#Antiviral efficacy of oral #ensitrelvir versus oral ritonavir-boosted #nirmatrelvir in #COVID19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

#Antiviral efficacy of oral #ensitrelvir versus oral ritonavir-boosted #nirmatrelvir in #COVID19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial, etidiohnew.blogspot.com/2025/10/anti...

it is likely to maintain efficacy against emerging Omicron subvariants, a potential limitation of neutralizing monoclonal antibody therapy. In vitro testing has also shown that Omicron subvariants remain relatively susceptible to #nirmatrelvir

Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19 | NEJM Clinical trials of treatments for coronavirus disease 2019 (Covid-19) have not shown a significant benefit of postexposure prophylaxis. We conducted a phase 2–3 double-blind trial to assess the eff...

#Evidence that #nirmatrelvir/ #ritonavir (#Paxlovid) is not effective as post-exposure prophylaxis for #COVID19 after #SARSCoV2 infection.
#MedSky 🧪

RAY1216 shows antiviral activities against #SARSCoV2 variants comparable to those of nirmatrelvir. It also shows improved pharmacokinetics in vivo ,suggesting that RAY1216 could be used without #ritonavir , which is co-administered with #nirmatrelvir.

The chemical structure of RAY1216; P1′ denotes the warhead moiety and P1–P4 denote the other chemical moieties. b, The chemical structure of SARS-CoV-2 Mpro inhibitor PF-07321332 (nirmatrelvir). c,d, Chemical structures of telaprevir (c) and boceprevir (d), both of which inhibit HCV NS3/4A protease.

#MedSky🧪 #IDSky #Drugsrepurposing #Immunopharmacology Preclinical evaluation of #SARSCoV2 #Mproinhibitor RAY1216 shows improved #pharmacokinetics vs #nirmatrelvir .RAY1216 shows #antiviral activities against #SARSCoV2 variants vs those of #nirmatrelvir.

Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors SARS-CoV-2 main protease (Mpro) is a validated antiviral drug target of nirmatrelvir, the active ingredient in Pfizer's oral drug Paxlovid. Drug-drug …

No cysteine protease inhibitors had been approved by @US_FDA before #Pfizer's #Paxlovid which contains the Mpro inhibitor #nirmatrelvir & the metabolic enhancer #ritonavir. 🔑 to the success of #nirmatrelvir is the choice of nitrile as the reactive warhead

www.sciencedirect.com/science/arti...

Although the orally active drug #nirmatrelvir
📌 www.sciencedirect.com/topics/pharm...
📌 www.nature.com/articles/s41...